journal article·2024-10

A Macrophage Membrane‐Functionalized, Reactive Oxygen Species‐Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management

Kai Qu, Yuan Zhong, Li Zhu, Nianlian Mou, Yu Cao, Jie Liu, Shuai Wu, Meng Yan, Fei Yan, Jiawei Li, Cheng Zhang, Guicheng Wu, Kun Zhang, Xian Qin, Wei Wu

Advanced Healthcare Materials· Volume 13· Issue 26
Publisher page

Abstract

Abstract Atherosclerosis (AS) management typically relies on therapeutic drug interventions, but these strategies typically have drawbacks, including poor site specificity, high systemic intake, and undesired side effects. The field of cell membrane camouflaged biomimetic nanomedicine offers the potential to address these challenges thanks to its ability to mimic the natural properties of cell membranes that enable enhanced biocompatibility, prolonged blood circulation, targeted drug delivery, and evasion of immune recognition, ultimately leading to improved therapeutic outcomes and reduced side effects. In this study, a novel biomimetic approach is developed to construct the M1 macrophage membrane‐coated nanoprodrug (MM@CD‐PBA‐RVT) for AS management. The advanced MM@CD‐PBA‐RVT nanotherapeutics are proved to be effective in inhibiting macrophage phagocytosis and facilitating the cargo delivery to the activated endothelial cells of AS lesion both in vitro and in vivo. Over the 30‐day period of nanotherapy, MM@CD‐PBA‐RVT is capable of significantly inhibiting the progression of AS, while also maintaining a favorable safety profile. In conclusion, the biomimetic MM@CD‐PBA‐RVT shows promise as feasible drug delivery systems for safe and effective anti‐AS applications.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immune cells in cancer · Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory for Biorheological Science and Technology of Ministry of Education State and Local Joint Engineering Laboratory for Vascular Implants Bioengineering College of Chongqing University Chongqing 400030 China

Chongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases Chongqing University Three Gorges Hospital Chongqing 404000 China

Jin Feng Laboratory Chongqing Chongqing 401329 China

Funding

National Natural Science Foundation of China · Postdoctoral Research Foundation of China

References (51)

Show source-provided references
1. 10.1038/s41586-021-03392-810.1038/s41586-021-03392-8 ↗
2. 10.1093/ndt/gfm11210.1093/ndt/gfm112 ↗
3. 10.1161/CIRCRESAHA.118.31359110.1161/CIRCRESAHA.118.313591 ↗
4. 10.1016/j.jacc.2005.09.06810.1016/j.jacc.2005.09.068 ↗
5. 10.1161/CIRCRESAHA.115.30761110.1161/CIRCRESAHA.115.307611 ↗
6. 10.1038/nm.253810.1038/nm.2538 ↗
7. 10.1136/neurintsurg-2011-01005110.1136/neurintsurg-2011-010051 ↗
8. 10.1016/j.ejvs.2021.10.03210.1016/j.ejvs.2021.10.032 ↗
9. 10.1161/ATVBAHA.118.31095810.1161/ATVBAHA.118.310958 ↗
10. 10.7150/thno.2267910.7150/thno.22679 ↗
11. 10.7150/thno.4784110.7150/thno.47841 ↗
12. 10.1186/s12951-018-0392-810.1186/s12951-018-0392-8 ↗
13. 10.1016/j.mam.2021.10105110.1016/j.mam.2021.101051 ↗
14. 10.1016/j.addr.2021.01.00510.1016/j.addr.2021.01.005 ↗
15. 10.1002/adma.20220612910.1002/adma.202206129 ↗
16. 10.1161/CIRCRESAHA.116.30932610.1161/CIRCRESAHA.116.309326 ↗
17. 10.1021/acsnano.1c0839110.1021/acsnano.1c08391 ↗
18. 10.1021/acsnano.0c0101210.1021/acsnano.0c01012 ↗
19. 10.1016/j.ejmech.2020.11299710.1016/j.ejmech.2020.112997 ↗
20. 10.1002/adma.20210843010.1002/adma.202108430 ↗
21. 10.1016/j.biomaterials.2022.12138710.1016/j.biomaterials.2022.121387 ↗
22. 10.34133/research.018810.34133/research.0188 ↗
23. 10.1002/hep.2660710.1002/hep.26607 ↗
24. 10.1016/j.freeradbiomed.2016.05.00310.1016/j.freeradbiomed.2016.05.003 ↗
25. 10.1128/mBio.02210-1510.1128/mBio.02210-15 ↗
26. 10.1002/smll.20200473510.1002/smll.202004735 ↗
27. 10.1038/nature1618510.1038/nature16185 ↗
28. 10.1016/j.jconrel.2019.12.02110.1016/j.jconrel.2019.12.021 ↗
29. 10.1016/j.carbpol.2022.11963210.1016/j.carbpol.2022.119632 ↗
30. 10.1002/smll.20220096710.1002/smll.202200967 ↗
31. 10.1021/acs.bioconjchem.8b0010310.1021/acs.bioconjchem.8b00103 ↗
32. 10.1016/j.jconrel.2022.06.02610.1016/j.jconrel.2022.06.026 ↗
33. 10.1002/smtd.20220028910.1002/smtd.202200289 ↗
34. 10.1186/s12951-022-01475-w10.1186/s12951-022-01475-w ↗
35. 10.1038/nature1537310.1038/nature15373 ↗
36. 10.1002/adma.20160620910.1002/adma.201606209 ↗
37. 10.1002/jcp.2642910.1002/jcp.26429 ↗
38. 10.1016/j.cell.2011.04.00510.1016/j.cell.2011.04.005 ↗
39. 10.1007/s11010-016-2724-z10.1007/s11010-016-2724-z ↗
40. 10.1161/CIRCRESAHA.115.30636110.1161/CIRCRESAHA.115.306361 ↗
41. 10.1007/s13402-019-00469-510.1007/s13402-019-00469-5 ↗
42. 10.1002/adhm.20210178810.1002/adhm.202101788 ↗
43. Cutolo M. · Clin. Exp. Rheumatol. · 1993 · 11 · 331
44. 10.1161/CIRCRESAHA.115.30625610.1161/CIRCRESAHA.115.306256 ↗
45. 10.1007/s00018-019-03371-310.1007/s00018-019-03371-3 ↗
46. 10.1016/j.cca.2019.10.03410.1016/j.cca.2019.10.034 ↗
47. 10.1124/pharmrev.120.00009610.1124/pharmrev.120.000096 ↗
48. 10.7150/thno.6121410.7150/thno.61214 ↗
49. 10.1002/adma.20190460710.1002/adma.201904607 ↗
50. 10.3389/fimmu.2021.63642710.3389/fimmu.2021.636427 ↗
51. 10.1021/acs.analchem.1c0056710.1021/acs.analchem.1c00567 ↗